Author + information
- Received May 6, 2019
- Accepted May 6, 2019
- Published online July 1, 2019.
- Leslee J. Shaw, PhDa,∗ (, )
- Ron Blankstein, MDb,
- David L. Brown, MDc,
- Sanket S. Dhruva, MD, MHSd,e,
- Pamela S. Douglas, MDf,
- Tessa S.S. Genders, MD, PhDf,
- Raymond J. Gibbons, MDg,
- John P. Greenwood, MDh,
- Raymond Kwong, MDi,
- Jonathon Leipsic, MDi,
- John J. Mahmarian, MDj,
- David Maron, MDk,
- Eike Nagel, MDl,
- Ed Nicol, MDm,
- Koen Nieman, MD, PhDk,
- Patricia A. Pellikka, MDg,
- Rita F. Redberg, MD, MScd,
- Jonathan Weir-McCall, MDi,
- Michelle C. Williams, MDn and
- Y. Chandrasekhar, MDo
- aWeill Cornell Medical College, New York, New YorkWeill Cornell Medical College, New York, New York
- bBrigham and Women's Hospital, Harvard Medical School, Boston, MassachusettsBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cWashington University School of Medicine, St. Louis, MissouriWashington University School of Medicine, St. Louis, Missouri
- dUniversity of California-San Francisco School of Medicine, San Francisco, CaliforniaUniversity of California-San Francisco School of Medicine, San Francisco, California
- eSan Francisco Veterans Affairs Medical Center, San Francisco, CaliforniaSan Francisco Veterans Affairs Medical Center, San Francisco, California
- fDuke Clinical Research Institute, Duke University School of Medicine, Durham, North CarolinaDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- gMayo Clinic, Rochester, MinnesotaMayo Clinic, Rochester, Minnesota
- hUniversity of Leeds, Leeds, United KingdomUniversity of Leeds, Leeds, United Kingdom
- iSt. Paul’s Hospital and University of British Columbia, Vancouver, British Columbia, CanadaSt. Paul’s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
- jThe Methodist Hospital, Houston, TexasThe Methodist Hospital, Houston, Texas
- kStanford University School of Medicine, Stanford, CaliforniaStanford University School of Medicine, Stanford, California
- lGoethe University Frankfurt, Frankfurt, GermanyGoethe University Frankfurt, Frankfurt, Germany
- mRoyal Brompton Hospital, London, United KingdomRoyal Brompton Hospital, London, United Kingdom
- nUniversity of Edinburgh, Edinburgh, ScotlandUniversity of Edinburgh, Edinburgh, Scotland
- oUniversity of Minnesota, Minneapolis, MinnesotaUniversity of Minnesota, Minneapolis, Minnesota
- ↵∗Address for correspondence:
Dr. Leslee J. Shaw, Weill Cornell Medical College, 407 East 61st Street, RR119, New York, New York 10065.
There has been a tremendous growth quantity of high-quality imaging evidence in the area of acute and stable ischemic heart disease (SIHD). A number of recent comparative effectiveness trials have spurned significant controversies in the field of cardiovascular imaging. The result of this evidence is that many health care policies and national guidelines have undergone significant revisions. With all of this evidence, many challenges remain and the optimal evaluation strategy for evaluation of patients presenting with chest pain remains ill-defined. This paper enlisted the guidance of numerous experts in the field of cardiovascular imaging to garner their perspective on available imaging research in chest pain syndromes. Each of these vignettes represent editorial perspectives and diverse opinions as to which, if any, should be the primary test in the evaluation of stable chest pain. These perspectives are not meant to be all inclusive but to highlight many of the commonly discussed controversies in the evaluation of chest pain symptoms. These perspectives are presented as a pre-amble to an upcoming American College of Cardiology/American Heart Association clinical practice guideline that is undergoing revision from the previous report published in 2012. The evidence has changed considerably since the 2012 SIHD guideline, and the current perspectives represent the diversity of available evidence as to the optimal imaging strategy for evaluation of the symptomatic patient.
Dr. Blankstein has received research support from Amgen and Astellas. Dr. Leipsic is a member of the institutional core laboratories for Edwards, Medtronic, Abbott, and Neovasc; and has been a consultant for and holds stock options for CIRCL, CVI, and Heartflow. Dr. Mahmarian has a relationship with Astellas USA. Dr. Nagel has received grant support and has been a consultant for Bayer AG; and has received speaker honoraria from Siemens Healthineers. Dr. Nicol has been a member of the Speakers Bureau for GE and Siemens; and has been a consultant for GE. Dr. Nieman has received unrestricted institutional research support from Siemens Healthineers, Bayer Healthcare, GE Healthcare, and Heartflow Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received May 6, 2019.
- Accepted May 6, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.